[1] Neuro-Ophthalmology Group, Ophthalmology Branch, Chinese Medical Association.Expert consensus on diagnosis and treatment of optic neuritis (2014[) J].Zhonghua Yan Ke Za Zhi, 2014, 50:459-463.[中华医学会眼科学分会神经眼科学组.视神经炎诊断和治疗专家共识(2014年)[J].中华眼科杂志, 2014, 50:459-463.] [2] World Health Organization.Hepatitis B vaccines:WHO position paper, July 2017-recommendations[J].Vaccine, 2019, 37:223-225. [3] Infectious Diseases Branch, Chinese Medical Association; Hepatology Branch, Chinese Medical Association.The guidelines of prevention and treatment for chronic hepatitis B (2019 version)[J].Zhonghua Gan Zang Bing Za Zhi, 2019, 27:938-961.[中华医学会感染病学分会, 中华医学会肝病学分会.慢性乙型肝炎防治指南(2019年版)[J].中华肝脏病杂志, 2019, 27:938-961.] [4] Curras-Martin D, Campbell N, Haroon A, Hossain MA, Asif A.Recurrent optic neuritis as the only manifestation of chronic hepatitis B virus flare:a case report[J].J Med Case Rep, 2018, 12:316. [5] Korkmaz A, Top Karti D, Unsal Bilgin YO, Karti O, Celebisoy N.Bilateral optic neuropathy revealing chronic hepatitis B infection:a report of a rare case[J].Neuroophthalmology, 2020, 45:403-406. [6] Teng D, Tan S, Yang M, Wang J, Zhao J, Xu Q, Wei S.A case report of hepatitis B related optic neuritis treated with plasma exchange[J].Medicine (Baltimore), 2019, 98:e15432. [7] Zhao S, Chen T, Peng C, Zhou H, Li H, Huang D, Xu Q, Wei S.The putative acceleration of optic neuritis when combined with chronic hepatitis B[J].J Neurol Sci, 2015, 358:207-212. [8] Zhu LP, Lu H, Yan R, Peng JT, Lu CF, Sun L, Zhang XJ.Clinical study of optic neuritis combined with viral hepatitis[J].Zhonghua Yan Ke Za Zhi, 2012, 48:428-431.[朱丽平, 卢海, 颜榕, 彭静婷, 陆长峰, 孙林, 张晓君.视神经炎伴发病毒性肝炎的临床研究[J].中华眼科杂志, 2012, 48:428-431.] [9] Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH.Asian-Pacific clinical practice guidelines on the management of hepatitis B:a 2015 update[J].Hepatol Int, 2016, 10:1-98. [10] Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG.The clinical course of neuromyelitis optica (Devic's syndrome[) J].Neurology, 1999, 53:1107-1114. [11] Tao Y, Wu D, Zhou L, Chen E, Liu C, Tang X, Jiang W, Han N, Li H, Tang H.Present and future therapies for chronic hepatitis B[J].Adv Exp Med Biol, 2020, 1179:137-186. [12] Cacoub P, Terrier B.Hepatitis B-related autoimmune manifestations[J].Rheum Dis Clin North Am, 2009, 35:125-137. [13] Ferro JM, Oliveira S.Neurologic manifestations of gastrointestinal and liver diseases[J].Curr Neurol Neurosci Rep, 2014, 14:487. [14] Xu CL, Wang DX.Peripheral neuropathy associated with viral hepatitis[J].Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2012, 12:480-482.[许春伶, 王得新.病毒性肝炎伴发周围神经病变[J].中国现代神经疾病杂志, 2012, 12:480-482.] [15] Neuroimmunology Branch, Chinese Society of Immunology.Chinese guidelines for the diagnosis and treatment of neuromyelitis optica spectrum disorders (2021 edition)[J].Zhongguo Shen Jing Mian Yi Xue He Shen Jing Bing Xue Za Zhi, 2021, 28:423-436.[中国免疫学会神经免疫分会.中国视神经脊髓炎谱系疾病诊断与治疗指南(2021版)[J].中国神经免疫学和神经病学杂志, 2021, 28:423-436.] [16] Heekin R, Gandhy C, Robertson D.Seronegative neuromyelitis optica spectrum disorder following exposure to hepatitis B vaccination[J].Case Rep Neurol, 2015, 7:78-83. [17] Toosy AT, Mason DF, Miller DH.Optic neuritis[J].Lancet Neurol, 2014, 13:83-99. [18] Jiang LB, Wang Q, Wei WB.Types and differential diagnosis of optic neuritis[J].Yan Ke, 2013, 22:364-369.[姜利斌, 王倩, 魏文斌.视神经炎分类与鉴别诊断[J].眼科, 2013, 22:364-369.] [19] Mastronardi FG, Moscarello MA.Molecules affecting myelin stability:a novel hypothesis regarding the pathogenesis of multiple sclerosis[J].J Neurosci Res, 2005, 80:301-308. [20] Yang L, Tan D, Piao H.Myelin basic protein citrullination in multiple sclerosis:a potential therapeutic target for the pathology[J].Neurochem Res, 2016, 41:1845-1856. [21] Spadaro M, Gerdes LA, Krumbholz M, Ertl-Wagner B, Thaler FS, Schuh E, Metz I, Blaschek A, Dick A, Brück W, Hohlfeld R, Meinl E, Kümpfel T.Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis[J].Neurol Neuroimmunol Neuroinflamm, 2016, 3:e257. [22] Thulasirajah S, Pohl D, Davila-Acosta J, Venkateswaran S.Myelin oligodendrocyte glycoprotein-associated pediatric central nervous system demyelination:clinical course, neuroimaging findings, and response to therapy[J].Neuropediatrics, 2016, 47:245-252. [23] Achiron LR.Postinfectious hepatitis B optic neuritis[J].Optom Vis Sci, 1994, 71:53-56. [24] Galli M, Morelli R, Casellato A, Perna MC.Retrobulbar optic neuritis in a patient with acute type B hepatitis[J].J Neurol Sci, 1986, 72:195-200. [25] Wang CR, Tsai HW.Human hepatitis viruses-associated cutaneous and systemic vasculitis[J].World J Gastroenterol, 2021, 27:19-36. [26] Chroni E, Thomopoulos C, Papapetropoulos S, Paschalis C, Karatza CL.A case of relapsing Guillain-Barré syndrome associated with exacerbation of chronic hepatitis B virus hepatitis[J].J Neurovirol, 2003, 9:408-410. [27] Babatin MA, AlJohani A.Demyelinating polyneuropathy associated with chronic inactive hepatitis B infection[J].BMJ Case Rep, 2021, 14:e237070. [28] Park SH, Yang SK, Lim YS, Shim JH, Yang DH, Jung KW, Kim KJ, Ye BD, Byeon JS, Myung SJ, Kim JH.Clinical courses of chronic hepatitis B virus infection and inflammatory bowel disease in patients with both diseases[J].Inflamm Bowel Dis, 2012, 18:2004-2010. [29] Pattullo V.Prevention of hepatitis B reactivation in the setting of immunosuppression[J].Clin Mol Hepatol, 2016, 22:219-237. [30] Hoofnagle JH.Reactivation of hepatitis B[J].Hepatology, 2009, 49(5 Suppl):S156-165. [31] Chang JJ, Lewin SR.Immunopathogenesis of hepatitis B virus infection[J].Immunol Cell Biol, 2007, 85:16-23. [32] Rehermann B, Ferrari C, Pasquinelli C, Chisari FV.The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response[J].Nat Med, 1996, 2:1104-1108. [33] Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT; American Gastroenterological Association Institute.American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy[J].Gastroenterology, 2015, 148:215-219. |